BR112019002127A2 - proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão - Google Patents
proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusãoInfo
- Publication number
- BR112019002127A2 BR112019002127A2 BR112019002127A BR112019002127A BR112019002127A2 BR 112019002127 A2 BR112019002127 A2 BR 112019002127A2 BR 112019002127 A BR112019002127 A BR 112019002127A BR 112019002127 A BR112019002127 A BR 112019002127A BR 112019002127 A2 BR112019002127 A2 BR 112019002127A2
- Authority
- BR
- Brazil
- Prior art keywords
- lair
- fusion protein
- antibody
- agents
- combination
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 230000000903 blocking effect Effects 0.000 abstract 2
- 238000004132 cross linking Methods 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
são fornecidas composições e métodos de uso das mesmas para modular o lair-1. por exemplo, são fornecidos agentes imunomoduladores que reduzem a expressão de lair-1, a ligação do ligante, a ligação cruzada, a sinalização negativa, ou uma combinação destas. esses agentes podem ser usados para aumentar uma resposta imune em um sujeito em necessidade. agentes exemplares incluem (i) um polipeptídeo ou proteína de fusão lair-2 solúvel, (ii) um polipeptídeo ou proteína de fusão lair-1 solúvel, (iii) um anticorpo anti-lair-1 com função bloqueadora, (iv) um anticorpo que esgota as células positivas para lair-1, e (y) combinações destes. também são fornecidos agentes imunomoduladores que aumentam a expressão de lair-1, a ligação do ligante, a ligação cruzada, a sinalização negativa, ou uma combinação destas. esses agentes podem ser usados para reduzir uma resposta imune em um sujeito em necessidade. agentes exemplares incluem: (i) um anticorpo anti-lair-1 com função ativadora, (ii) um anticorpo anti-lair-2 com função bloqueadora, e (iii) uma combinação destes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370334P | 2016-08-03 | 2016-08-03 | |
US201762450300P | 2017-01-25 | 2017-01-25 | |
PCT/US2017/045310 WO2018027039A1 (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for modulating lair signal transduction |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002127A2 true BR112019002127A2 (pt) | 2019-09-17 |
Family
ID=61074186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002127A BR112019002127A2 (pt) | 2016-08-03 | 2017-08-03 | proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210363240A1 (pt) |
EP (1) | EP3496746A4 (pt) |
JP (2) | JP2019528311A (pt) |
KR (2) | KR20190044070A (pt) |
CN (1) | CN109789197A (pt) |
AU (1) | AU2017306560A1 (pt) |
BR (1) | BR112019002127A2 (pt) |
CA (1) | CA3032826A1 (pt) |
RU (1) | RU2757394C2 (pt) |
WO (1) | WO2018027039A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
KR20210004888A (ko) * | 2019-07-04 | 2021-01-13 | 주식회사 굳티셀 | T 세포의 세포 표면 항원 및 이의 다양한 용도 |
JP2021176829A (ja) * | 2019-07-12 | 2021-11-11 | 国立大学法人京都大学 | 歯の再生治療のためのusag−1を標的分子とした中和抗体 |
IL303712A (en) * | 2020-12-18 | 2023-08-01 | Cullinan Amber Corp | Bifunctional linear-collagen immunomodulatory molecules, and methods thereof |
WO2023122618A1 (en) * | 2021-12-21 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody |
WO2023173091A1 (en) | 2022-03-11 | 2023-09-14 | Ngm Biopharmaceuticals, Inc. | Osteoclast-associated ig-like receptor (oscar) and methods of use thereof |
WO2024022495A1 (en) * | 2022-07-28 | 2024-02-01 | Concept To Medicine Biotech Co., Ltd. | Anti-MerTK ANTIBODIES AND USES THEREOF |
WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2004850A2 (en) * | 2006-03-08 | 2008-12-24 | Universitair Medisch Centrum Utrecht | Interfering in activation of an immune cell by influencing interaction of lair and collagen. |
FR2909092B1 (fr) * | 2006-11-24 | 2012-10-19 | Pf Medicament | Nouveaux anticorps anti-proliferation |
EP2036570A1 (en) * | 2007-09-13 | 2009-03-18 | UMC Utrecht Holding B.V. | Means and methods for influencing platelet-collagen interaction |
EA201170375A1 (ru) * | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
US20110268741A1 (en) * | 2009-01-05 | 2011-11-03 | The Johns Hopkins University | Immunotherapy for Contact Dermatitis Using Co-Signal Regulation |
US8399624B1 (en) * | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
EP2895503B1 (en) * | 2012-09-13 | 2019-03-27 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
-
2017
- 2017-08-03 KR KR1020197005926A patent/KR20190044070A/ko not_active Application Discontinuation
- 2017-08-03 CN CN201780060801.9A patent/CN109789197A/zh active Pending
- 2017-08-03 JP JP2019527776A patent/JP2019528311A/ja active Pending
- 2017-08-03 CA CA3032826A patent/CA3032826A1/en active Pending
- 2017-08-03 EP EP17837690.1A patent/EP3496746A4/en active Pending
- 2017-08-03 AU AU2017306560A patent/AU2017306560A1/en active Pending
- 2017-08-03 BR BR112019002127A patent/BR112019002127A2/pt unknown
- 2017-08-03 RU RU2019105294A patent/RU2757394C2/ru active
- 2017-08-03 US US16/321,726 patent/US20210363240A1/en active Pending
- 2017-08-03 KR KR1020247006978A patent/KR20240035633A/ko active Application Filing
- 2017-08-03 WO PCT/US2017/045310 patent/WO2018027039A1/en unknown
-
2023
- 2023-05-30 JP JP2023088687A patent/JP2023109983A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3496746A1 (en) | 2019-06-19 |
KR20190044070A (ko) | 2019-04-29 |
WO2018027039A1 (en) | 2018-02-08 |
RU2757394C2 (ru) | 2021-10-14 |
AU2017306560A1 (en) | 2019-02-21 |
KR20240035633A (ko) | 2024-03-15 |
JP2023109983A (ja) | 2023-08-08 |
CN109789197A (zh) | 2019-05-21 |
WO2018027039A8 (en) | 2019-03-07 |
JP2019528311A (ja) | 2019-10-10 |
CA3032826A1 (en) | 2018-02-08 |
RU2019105294A3 (pt) | 2020-09-21 |
RU2019105294A (ru) | 2020-09-04 |
US20210363240A1 (en) | 2021-11-25 |
EP3496746A4 (en) | 2020-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019002127A2 (pt) | proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão | |
MX2019013312A (es) | Composiciones para facilitar la fusion de membranas y usos de estas. | |
BR112018071584A2 (pt) | métodos para modular de maneira seletiva a ativida-de de subtipos distintos de células | |
MX2022006002A (es) | Proteinas de fusion inmunomoduladoras y usos de las mismas. | |
MX2019010812A (es) | Proteinas de fusion inmunomoduladoras y sus usos. | |
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
BR112021016178A2 (pt) | Células-tronco doadoras universais e métodos relacionados | |
MX2020002596A (es) | Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. | |
PH12018500183A1 (en) | Novel anti-pd-1 antibodies | |
PH12018500269A1 (en) | Constructs having a sirp-alpha domain or variant thereof | |
EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
BR112019023071A2 (pt) | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas | |
BR112018008011A2 (pt) | proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv | |
CO2017002166A2 (es) | Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa | |
BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
BR112018002039A2 (pt) | proteínas de fusão gitrl e usos das mesmas | |
EA201890729A1 (ru) | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками | |
MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
WO2015066551A3 (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
EA201891142A1 (ru) | Контроль клеточных окислительно-восстановительных уровней | |
BR112015026823A2 (pt) | Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada | |
AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |